Stockreport

Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF R&D Expenses: Decreased in Q3 2024 compared to the prior year, primarily due to lower COVID-19 spending, offset by higher HCV Phase 2 trial spending. G&A Expenses: De [Read more]